![John Aballi, President and Chief Executive Officer. [NASDAQ XGN] at Exagen](https://exagen.wpenginepowered.com/wp-content/uploads/2022/11/John-A-Headshot.png){kind=small}
Sera Prognostics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Utah, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2749 E Parleys Way Ste 200, Salt Lake Ci...Phone Number
(801) 990-0520Website
www.seraprognostics.comRevenue
<$5 MillionStock Symbol
SERAIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Sera Prognostics
Sera Prognostics was founded to develop diagnostic tests for the early prediction of a womans individualized risk of premature birth, preeclampsia, and other pregnancy complications. Seras tests are designed to give women and their physicians the power and time to make a difference in maternal and newborn health with individualized treatment and care plans.Explore more
Popular SearchesSera Prognostics IncSera PrognosticsSIC Code 38,382NAICS Code 33,334Ticker NASDAQ: SERAShow moreSera Prognostics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sera Prognostics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Sera Prognostics launches new products
Check out if Sera Prognostics is spiking on competitors!
Funding: Get notified immidiatlly once Sera Prognostics has new funding data
Check if Sera Prognostics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Sera Prognostics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Sera Prognostics
Sera Prognostics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Sera Prognostics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Sera Prognostics
Find more new buyers
Compare Similar Companies to Sera Prognostics
Compare insights from companies similar to Sera Prognostics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sera Prognostics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sera Prognostics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sera Prognostics.
Sera Prognostics financials insights
Gather financial insights about Sera Prognostics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Debt
$4.5M
2014
Private Equity
$9.2M
Private Equity
$5M
2015
Series B
$25M
Debt
$10M
2017
Series C
$40M
2019
Series D
$36M
2020
Debt
$1M
2021
Series E
$100M
Share Placement
$75M
Sera Prognostics Tech Stack
A closer look at the technologies used by Sera Prognostics
See more technologies
Most Recent Scoops
Project
Sera Prognostics has begun engagement with the Illinois Department of Healthcare and Family Services, managed Medicaid organizations, and provider stakeholders following the passage of Illinois legislation requiring Medicaid coverage and reimbursement for proteomic blood tests used to identify and manage the risk of spontaneous preterm birth, including associated care management services. Illinois is the first state to formally recognize the clinical and health economic value of PreTRM Test-Guided Care, which Sera Prognostics believes can serve as a blueprint for similar initiatives nationwide.
Compliance, Governmental Affairs & Regulation, Medical Research, Healthcare Operations, Regulations
Project
Sera Prognostics has published a PRIME subgroup analysis focused on first-time mothers, demonstrating a 22% reduction in NICU admissions, a twofold reduction among newborns following spontaneous preterm birth, and a 30% reduction in severe composite neonatal morbidity, with a number needed to screen and treat of just 28 patients to prevent one NICU admission. First-time mothers represent approximately 40% of pregnancies in the United States, underscoring the significance of this data for broader adoption of biology-based risk assessment.
Earnings
Sera Prognostics has reported selling, general, and administrative expenses of $6.5 million for Q2 2026, compared to $6.0 million in the prior year period, reflecting investments in targeted commercial activities, marketing programs, and strategic commercial hires.
Earnings, Spending/Investment, Finance
Project
Sera Prognostics has outlined its Illinois Medicaid penetration expectations, projecting that the first six months following the July 1 reimbursement effective date will focus on contracting and awareness building, with 1% to 2% penetration of the approximately 50,000 Medicaid lives considered prudent for 2027, growing to 2% to 4% in the following year and 5% by year three, consistent with benchmarks observed for other leading diagnostic and screening tests.
Forecasting, Contracts
Earnings
Earnings, Business Finance, Finance, Financial Operations
Sera Prognostics News & Media
SERA PROGNOSTICS APPOINTS SCOTT GLEASON CHIEF FINANCIAL OFFICER
SALT LAKE CITY, Aug. 19, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced today that Scott Gleason has been...Sera Prognostics Q2 Earnings Call Highlights
Sera Prognostics (NASDAQ:SERA) reported modest second-quarter revenue while outlining progress in payer engagement, Illinois Medicaid policy, clinical evidence and European regulatory preparations for its PreTRM Test-guided care platform. Revenue for the quarter ended June 30 was $30,000, comparedPRIME SUBGROUP ANALYSIS DEMONSTRATES 22% REDUCTION IN NICU ADMISSIONS IN FIRST-TIME PREGNANCIES USING PreTRM® Test-GUIDED CARE
-- Study Highlights Screening Efficiency and Potential Cost Savings in a Large Underserved Population -- SALT LAKE CITY, July 9, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative...SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS
SALT LAKE CITY, June 30, 2026 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Mark Capone will join its...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sera Prognostics
Sign Up For FreeTo access detailed company insights
Sera Prognostics was founded to develop diagnostic tests for the early prediction of a womans individualized risk of premature birth, preeclampsia, and other pregnancy complications. Seras tests are designed to give women and their physicians the power and time to make a difference in maternal and newborn health with individualized treatment and ca... Read More
